Timing of OMERACT core domain measurement in gout clinical trials: a systematic review of randomised trials.

In 30 seconds

This systematic review evaluated the timing and reporting of core domain measurements in 43 randomized trials of urate-lowering therapy and gout flares. The study found significant variability in measurement frequencies, with serum urate and gout flares typically assessed monthly. Reporting of all measurements was inconsistent, ranging from 83% for serum urate to 0% for activity limitation.

Key findings

• Core domains in urate-lowering therapy trials were measured at seven different frequencies.
• Serum urate and gout flares were most commonly measured monthly.
• Reporting of all collected measurements varied from 83% for serum urate to 0% for activity limitation.
• In gout flare trials, pain was reported in 93% of trials, while joint tenderness was reported in only 37.5%.

Why it matters

Understanding the timing and consistency of core domain measurements in gout trials is crucial for improving trial design and ensuring reliable outcomes. This can enhance the comparability of results across studies and inform clinical practice.